Global
   
Include All CSL Behring Country Sites

2000 - present

Also in this section

2000 - ZLB Bioplasma Established

In June 2000 CSL signed an agreement to acquire the plasma fractionation assets and business (ZLB) from Rotkreuzstiftung Zentrallaboratorium Blutspendedientst SRK, a non-profit organisation affiliated with the Swiss Red Cross and with strong links to the international family of Red Cross organisations. ZLB is the fifth largest manufacturer of plasma products worldwide.

CSL Bioplasma launches new chromatography based plasma product portfolio.


2001 - ZLB Plasma Services Established

ZLB Plasma Services commenced operations in September 2001 following CSL's acquisition of 47 US-based plasma collection centres and associated laboratory facilities from Nabi. This acquisition secures plasma supply for the continued expansion of ZLB Bioplasma.


2002 - Expansion of Parkville Influenza Plant

CSL expands operations, effectively doubling the production of influenza vaccine to supply the demands in the Northern and Southern hemispheres.

CSL introduces Menjugate to the Australian market. Menjugate is a conjugated meningococcal C vaccine licensed from Chiron Corporation.

Opening of first regional office in Hong Kong.


2003 - CSL's thiomersal-free Influenza Vaccine Launched

Launch of CSL's thiomersal-free Fluvax influenza vaccine.

CSL Bioplasma's new purpose-built nucleic acid testing (NAT) laboratory commissioned.

CSL obtains US Human Papillomavirus Patent.


2004 - CSL Goes Global

CSL completes the acquisition of Aventis Behring, combining it with ZLB Bioplasma to create ZLB Behring, now known as CSL Behring, a global leader in plasma therapeutics.

Sale of Animal Health business to Pfizer Inc resulted in net proceeds of $161.6 million.


2005 - GARDASIL® – A Vaccine Against Cervical Cancer

CSL’s collaboration with Merck & Co. Inc and the University of Queensland to develop a cervical cancer vaccine succeeds. The product enters Phase III clinical trials and in 2006 receives FDA approval.


2006 – CSL acquires Zenyth Therapeutics and Vivaglobin® approved in U.K. and U.S.

Vivaglobin® is licensed for use in the U.K. and U.S. for adults and children who require antibody replacement due to primary immunodeficiency.
CSL acquires Zenyth Therapeutics Limited, strengthening CSL’s investment in developing products based on recombinant monoclonal antibodies.


2007 - Privigen® approved in the U.S.
Privigen® is the first proline-stabilised liquid intravenous immunoglobulin (IVIg) ready for immediate use, requiring no refrigeration or reconstitution. Privigen® approved by FDA
Biologics License Application (BLA) was filed with the FDA for the registration of CSL’s influenza vaccine in the U.S.


2008 - Privigen® launched in the U.S.
CSL signed a five year agreement with the Canadian Blood Service to fractionate Canadian plasma and supply a broad range of plasma products.
CSL launched Privigen® in the U.S.


2009 – CSL responds to the H1N1 influenza pandemic
CSL conducted clinical trials of its H1N1 pandemic influenza vaccine. CSL supplied its H1N1 pandemic influenza vaccine to Australia, U.S., Singapore, Canada and Germany. CSL also donated vaccine to the World Health Organisation.
U.S. Food and Drug Administration (FDA) granted CSL Behring seven-years of orphan-drug exclusivity for RiaSTAP™, the first FDA-approved treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency.
FDA, EMEA, Swissmedic and TGA approve new state-of-the-art immunoglobulin manufacturing plant at Bern, Switzerland manufacturing facility.

CSL Plasma opens one of the world's largest and most advanced plasma testing laboratories in Knoxville, Tennessee, USA.
The U.S. Food and Drug Administration (FDA) granted marketing approval for Berinert® C1-esterase inhibitor, the country's first and only therapy for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE).
CSL signed a new eight year agreement with the National Blood Authority to fractionate Australian plasma and supply a broad range of plasma products.


2010 - Hizentra® launched in the U.S.
CSL launched Hizentra®, our new 20% liquid subcutaneous immunoglobulin, in the U.S.